Plasma tetranectin levels in patients with unstable and stable angina

Fibrinolysis and Proteolysis

Volumn 12, Issue 6, 1998, Pages 353-359

  Kopeikina, L T ^a   Kamper, E F ^a   Mantas, A ^b   Kremastlnos, D ^b   Stavridis, J C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRONECTIN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETRANECTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032433405     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80393-7     Document Type: Article

References (25)

1. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994; 23: 809-813.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
3. van der Wal AC, Becker AE, van der Loos CM et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
4. Lupu F, Gerard D, Esmail A, Moradoghli-Haftvani A, Kakkar VV. The role of plasminogen activators in the development of atherosclerotic and restenotic lesions. Fibrinolysis 1996; 10(suppl 2):33-35.
5. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metallo-proteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
6. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986; 156: 327-333.
7. Durkin ME, Naylor SL, Albrechtsen R, Wewer UM. Assignment of the gene for human tetranectin (TNA) to chromosome 3p22→p21.3 by somatic cell hybrid mapping. Cytogenet Cell Genet 1997; 76: 39-40.
8. Kluft C, Los P, Clemmensen I. Calcium-dependent binding of tetranectin to fibrin. Thromb Res 1989; 55: 233-238.
9. Kluft C, Jie AFH, Los P, de Wit E, Havekes L. Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. Biochem Biophys Res Comm 1989; 161: 427-433.
10. Nielsen BB, Kastrup JS, Rasmussen H et al. Crystal structure of tetranectin, a trimeric plasminogen-binding protein with an ahelical coiled coil. FEBS Letters 1997; 412: 388-396.
11. Christensen L, Clemmensen I. Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme. Histochemistry 1989; 92: 29-35.
12. Wewer UM, Albrechtsen R. Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer. Lab Invest 1992; 67: 253-262.
13. Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis J. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 262-268.
14. Kamper EF, Kopeikina LT, Manias A, Stefanadis C, Toutouzas P, Stavridis J. Tetranectin levels in patients with acute myocardial infarction and their alterations during thrombolytic treatment. Ann Clin Biochem 1998; 35: 400-407.
15. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy adults: implication for reference interval and epidemiologic methods. Clin Chem 1997; 43: 52-58.
16. Soria C, Soria J, Mirshahi MC et al. Dynamic coronary fibrinolysis evaluation in patients with myocardial infarction and unstable angina by specific plasma fibrin degradation product determination. Thromb Res 1987; 45: 383-392.
17. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-2063.
18. Haverkate F. Low-grade acute-phase reactions in arterosclerosis and the consequencies for haemostatic risk factors. Fibrinolysis 1992; 6(suppl 3): 17-18.
19. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
20. Toss H, Lindal B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997; 96: 4204-4210.
21. Stouthard JML, Levi M, Hack CE et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-742.
22. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
23. Six AJ, Liem MK, Dooijewaard G et al. The acute-phase reaction of the fibrinolytic system in acute myocardial infarction and unstable angina. In: P. Glas-Greenwalt, (ed.) Fibrinolysis in disease: molecular and hemovascular aspects of fibrinolysis. CRC Press, Inc. 1995: 92-100.
24. Hogdall CK, Christiansen M, Brihmer C. Serum tetranectin in patients with acute pelvic inflammatory disease (PID). Acta Obstet Gynecol Scand 1995; 74: 203-207.
25. Kamper EF, Kopeikina LT, Trontzas P, Kyriazis G, Vaiopoulos G, Stavridis J. Comparative study of tetranectin levels in serum and synovial fluid of patients with rheumatoid arthritis, seronegative spondylarthritis and osteoarthritis. Clin Rheumatol 1998; 17: 318-324.